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OBJECTIVE: There are no pharmacoeconomic studies perform
to date comparing voriconazole and liposomal Amphotericin B
(LAB) for the treatment of systemic fungal infections. The aim
of this study was to perform an economic evaluation of voricona-
zole versus LAB for the treatment of invasive aspergillosis and
candidiasis. METHODS: A cost-minimization analysis was per-
formed from the hospital perspective in 2005, as the same efﬁ-
cacy was assumed. A systematic review of available literature
was performed between 1996 and 2005, in order to obtain the
efﬁcacy and incidence of drug-related adverse events (AE) for
each treatment group. Duration of treatment (intravenous: 15.42
days; oral: 4.49 days; the same for both treatments) and mean
weight of patients (68.6Kg) were obtained from a local study:
The Fungcost study (Peiro S. Value Health 2002;5:564). Only
direct costs per episode were considered; medications (iv and
oral) at their hospital selling prices; the cost of monitoring AE;
and administration costs (obtained from a national cost data-
base). Voriconazol was the oral treatment in both groups. The
most important AE for each treatment (and the way to monitor
them) were: hepatotoxicity with voriconazole -13.97%—(two
chemistries and hematologic tests during the treatment period);
and nefrotoxicity with LAB -12.84%—(a daily creatinine clear-
ance measurement). Mean cost per episode and incremental cost
were calculated. RESULTS: Mean cost per episode was €6073.43
(iv treatment 94.22%) for voriconazole, and €8794.33 (iv:
95.78%) for LAB in the treatment of invasive aspergillosis, with
an incremental cost of €2486.90 (28.28%) The treatment of can-
didiasis showed a mean cost of €6307.43 (iv: 94.22%) and
€8779.92 (95.93%), respectively, with an incremental cost of
€2472.48 (28.16%). Results were robust to the sensitivity analy-
sis. CONCLUSION: Using costs and treatment patterns of
fungal infections in Spain, voriconazole is more cost-effective
than LAB for the treatment of invasive candidiasis and
aspergillosis.
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OBJECTIVE: Human Papillomavirus infection is the principal
cause of cervical cancer and most cervical neoplasia. Despite
available screening and treatment, cervical cancer remains an
important public health problem. HPV vaccination studies have
shown high efﬁcacy against HPV-induced cervical lesions. Prior
to implementing a vaccination programme, data about cervical
dysplasia and annual treatment costs are critical. This study
assessed resource use and costs for Pap III, IIID and IV patients
in Germany. METHODS: A one-year retrospective chart review
of 138 patients, diagnosed with Pap III, IIID or IV between Feb-
ruary—March 2004, was conducted to assess clinical and
resource use. Resources included consultations, medications,
procedures, diagnostics, adverse events and hospital stays. Unit
costs from ofﬁcial sources were applied to calculate the average
cost per patient. RESULTS: Most patients had Pap IIID (n = 79)
vs. Pap III (n = 27) or Pap IV (n = 32). Mean duration of treat-
ment was 4.4, 5.5, and 4.9 months for Pap III, IIID and IV
respectively. Pap IIID patients had on average 4.6 gynaecologist
consultations vs. 4.2 and 5.6 for Pap III and IV respectively. Most
common diagnostic tests were Pap-smears (99%) and col-
poscopy (in 89%, 73% and 75% of Pap III, IIID and IV). Typ-
ically, patients were treated by conisation (in 22%, 27% and
84% of Pap III, IIID and IV). More Pap IV patients had hys-
terectomies (22% vs. 4% for Pap III) and laser coagulation
(12.5% vs. 4% for Pap IIID). 33% of the patients were hospi-
talised (mean 7.4 ± 8.3 days). The estimated average annual cost
per patient was €1070, €955 and €3240 for Pap III, IIID and Pap
IV, including 40% indirect costs. CONCLUSION: The cost of
managing pre-cancerous cervical lesions in Germany is high. An
HPV vaccine preventing many of these lesions could avert much
of these costs.
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OBJECTIVE: Human Papillomavirus (HPV) is the main cause
of genital warts (GWs) and a necessary cause of cervical cancer
(CC). There is a lifetime HPV infection risk in women of
55–75%. Genitourinary Medicine (GUM) clinics and CC screen-
ing programmes help in the detection and treatment of GWs and
deceleration of progression to cancerous lesions. This study esti-
mated the annual National Health Service (NHS) costs of diag-
nosing and managing HPV related diseases in a pre-HPV vaccine
era. METHODS: Data for ﬁrst and recurrent GWs episodes were
obtained from the Health Protection Agency and management
pathways from GUM clinicians. The number of women screened
for CC, results, and procedures undertaken for abnormal ﬁnd-
ings were obtained from a variety of sources (e.g., Government
Statistical Service, Regional Screening Programmes; adjusted to
2003). Annual new cases of CC were obtained from GLOBO-
CAN, 2002. Resource costs (2003) included screening tests, clin-
ician visits, diagnostic and treatment procedures, hospital
admissions and drugs. Sensitivity analyses examined the range of
treatment patterns and costs. RESULTS: In 2003, GUM clinics
treated almost 114,000 patients with GWs. Topical creams were
the ﬁrst line treatment for the majority (77%) followed by
cryotherapy or combination of the two. An average 26% of
patients returned to complete their treatment. Total annual costs
for GWs were £22.4 million. In 2003, 4.8 million CC screening
tests were conducted at a cost of £104.5 million. Over 227,209
women were referred for colposcopy, costing £34 million for the
diagnosis and treatment of precancerous lesions. Newly identi-
ﬁed CC cases (N = 3308) and hospital admissions for prevalent
CC cases in 2003 cost £43.7 million. Estimated total 2003 NHS
costs related to HPV were £204.6 million (range: £181.3–£209.7
million). CONCLUSION: Preventing HPV related diseases
through vaccination with a quadrivalent vaccine could result in
cost offsets and more efﬁcient resource allocation.
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OBJECTIVES: Human Papillomavirus (HPV) infections, includ-
ing genital warts (GW), are common. Current treatments are not
